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http://dx.doi.org/10.1016/j.bgm.201Abstract Atherosclerosis is a chronic inflammatory vascular disease, and an association be-
tween elevated blood lipids and atherosclerosis has previously been recognized. Low-density
lipoprotein cholesterol (LDLc) levels have also been recognized as indicators of cardiovascular
complications, but two people who have exactly the same LDLc concentrations may have
different risk factors, and the National Cholesterol Education Program Adult Treatment Panel
III (NCEP ATP III) guidelines recommend patching non-high-density lipoprotein cholesterol (non-
HDLc) as another indicator. The present study investigated diabetic dyslipidemia to determine
if there is a correlation between dyslipidemia and C-reactive protein (CRP). The data shows
that non-HDLc was an independent risk factor for cardiovascular events in patients with dia-
betes and that CRP could indicate the risk of future cardiovascular events in both high-risk
and healthy individuals.
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108 W.-T. Hsu et al.Introduction samples was performed using a Roche Cobas c501 (RocheStudies have shown that dyslipidemia in diabetic patients is
associated with cases of fatal cardiovascular disease.1 High
lipid concentrations are considered to be a very strong risk
factor, and studies have been focused on the association
between elevated blood lipids and atherosclerosis.2,3 Low-
density lipoprotein (LDL) levels have already been recog-
nized as indicators of cardiovascular complications; howev-
er, patients with the same LDL cholesterol (LDLc)
concentrations may have different risk factors. Therefore,
theNational Cholesterol Education ProgramAdult Treatment
Panel III (NCEP ATP III) guidelines recommended considering
non-high-density lipoprotein cholesterol (non-HDLc) levels
as another indicator, and suggest that diabetic patients will
typically have LDLc < 100 mg/dL and non-HDLc < 130 mg/
dL.4 In addition, it is believed that atherosclerosis is a
chronic inflammatory vascular disease.5 Because lipopro-
teins can penetrate the arterial wall and inducemacrophage
foam cell formation, such penetration is closely related to
the formation of atherosclerosis.6e8 Therefore, early control
of lipids can reduce cardiovascular morbidity and mortality
in diabetic patients.9 This study was conducted to investi-
gate the correlation between non-HDLc and C-reactive pro-
tein (CRP) in diabetic patients, and to investigate whether
elevated non-HDLc may increase the risk of cardiovascular
disease, even as the patient’s LDLc levels equal or lower than
the NCEP target.
Materials and methods
Blood samples were collected from 104 c (T2D) patients and
21 randomized controlled patients without diabetes who
had appointments with an endocrinologist; all of the pa-
tients signed informed consent forms. Fasting blood sam-
ples were taken for the determination of fasting blood
glucose (FBG), total cholesterol (TC), HDLc, LDLc, triglyc-
eride (TG), and CRP levels. Automatic analysis of theFigure 1 The standardized level of fasting blood glucose
(FBG) and C-reactive protein (CRP) of patients with type 2
diabetes (T2D) were higher than those of randomized
controlled patients without diabetes, showing highly significant
differences (***p Z 0.001;*p Z 0.046).Diagnostics GmbH, Mannheim, Germany). Non-HDLc levels
were calculated by the Friedwald and Frederickson for-
mula. The concentration of each result was divided by the
average concentration of the control group and the ratio
was took as standardized level.
Results
As expected, the standardized levels of FBG and CRP in the
104 patients with T2D (1.48  0.67 and 3.31  5.20,
respectively) were higher than those of the randomized
controlled patients, showing highly significant differences
(***p Z 0.001; *p Z 0.046; Fig. 1). To further study the
relation between CRP levels and T2D, the 104 T2D patients
were studied according to subclasses of LDLc levels, and the
standardized levels of LDLc and CRP in 74 patients with
LDLc > 100 mg/dL (1.18  0.21 and 3.75  5.90, respec-
tively), were higher than those with LDLc < 100 mg/dL
(0.72  0.13 and 2.21  2.61, respectively), among the T2DFigure 2 The standardized level of (A) low-density lipopro-
tein cholesterol (LDLc) and (B) C-reactive protein (CRP) in type
2 diabetic (T2D) patients with LDLc > 100 mg/dL were higher
than those with LDL cholesterol < 100 mg/dL and randomized
controlled patients without diabetes, showing highly significant
differences (***p Z 0.001; *p Z 0.037).
Figure 3 The standardized level of (A) non-high-density li-
poprotein cholesterol (non-HDLc) and (B) C-reactive protein
(CRP) in type 2 diabetic (T2D) patients with non-HDLc> 130mg/
dL were higher than those with non-HDLc < 130 mg/dL and
randomized controlled patients (***p < 0.001; *pZ 0.021), but
the standardized level of CRP did not show significant differ-
ences between randomized controlled patients and T2D pa-
tients with non-HDLc < 130 mg/dL (pZ 0.103).
Non-HDLc and CRP in DM patients 109patients and randomized controlled patients, showing highly
significant differences in CRP (*p Z 0.037; Fig. 2). One
hundred and four T2D patients were studied again after
subclassification of non-HDLc levels, and the standardized
levels of non-HDLc and CRP in 62 patients with non-
HDLc > 130 mg/dL (1.30  0.79 and 4.26  6.29, respec-
tively), were higher than those with non-HDLc < 130 mg/dL
(0.81  0.37 and 1.90  2.37, respectively) among T2D pa-
tients and controlled patients, showing highly significant
differences of CRP in randomized controlled patients
(*pZ 0.021), although no significant differences in CRP were
found among the randomized controlled patients with non-
HDLc < 130 mg/dL (p Z 0.103; Fig. 3).
Discussion
Previous studies support the importance of CRP as an in-
dependent risk factor for cardiovascular events.10 Theseresults also suggest the association between non-HDLc and
inflammation, even in a more severe stage of cardiovas-
cular disease (CAD). Non-HDLc as an independent risk fac-
tor for T2D patients may also be a strong predictor of
cardiovascular disease.11 In conclusion, our study confirmed
that non-HDLc is an independent risk factor for cardiovas-
cular events in T2D patients. In Figs. 2 and 3, the data of
CRP may also indicate the risk of cardiovascular disease,
even at low concentrations of LDLc, and show significant
differences between low concentrations and high concen-
trations of non-HDLc in T2D patients. Monitoring HDLc
concentrations may reduce the cardiovascular risk. There-
fore, non-HDLc and CRP are useful markers for predicting
cardiovascular events in both high-risk and healthy
individuals.Acknowledgments
Many thanks for Armed Force Taichung General Hospital
that provided full funding for this research.References
1. Sultan A, Thuan JF, Avignon A, et al. Primary prevention of
cardiovascular events and type 2 diabetes: should we pri-
oritize our interventions? Diabetes Metab. 2006;32:
559e567.
2. Lo`pez-Jaramillo P, Casas JP, Bautista L, et al. An integrated
proposal to explain the epidemic of cardiovascular disease in a
developing country: from socioeconomic factors to free radi-
cals. Cardiology. 2001;96:1e6.
3. Sanchez-Recalde A, Kaski JC. Diabetes mellitus, inflamma-
tion and coronary atherosclerosis: current and future per-
spectives. Revista Espanola de Cardiologia. 2001;54:
751e763.
4. Frost PH, Havel RJ. Rationale for use of non-high-density li-
poprotein cholesterol rather than low-density lipoprotein
cholesterol as a tool for lipoprotein cholesterol screening and
assessment of risk and therapy. Am J Cardiol. 1998;81:
26Be31B.
5. Libby P, Ridker PM, Maseri A, et al. Inflammation and athero-
sclerosis. Circulation. 2002;105:1135e1143.
6. Sniderman AD, Scantlebury T, Cianflone K, et al. Hyper-
triglyceridemic hyperapoB: the unappreciated atherogenic
dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern
Med. 2001;135:447e459.
7. Krentz AJ. Lipoprotein abnormalities and their consequences
for patients with type 2 diabetes. Diabetes Obes Metab. 2003;
5:19e27.
8. Hodis HN. Triglyceride-rich lipoprotein remnant particles and
risk of atherosclerosis. Circulation. 1999;99:2852e2854.
9. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and car-
diovascular disease: a statement for healthcare professionals
from the American Heart Association. Circulation. 1999;
7(100):1134e1146.
10. Ridker PM, Buring JE, Rifai N, et al. Development and valida-
tion of improved algorithms for the assessment of global car-
diovascular risk in women: the Reynolds risk score. J Am Med
Assoc. 2007;297:611e619.
11. Lu W, Resnick HE, Jablonski KA, et al. Howard BV: NoneHDL
cholesterol as a predictor of cardiovascular disease in type 2
diabetes: The Strong Heart Study. Diabetes Care. 2003;26:
16e23.
